4d Pharma PLC Participation in Chardan Conference

TIDMDDDD

4d Pharma PLC

16 March 2020

4D pharma plc

(the "Company" or "4D")

4D announces participation in Chardan Microbiome Medicines Summit

LEEDS, UK -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces its participation in the 2nd Annual Chardan Capital Markets LLC Microbiome Medicines Summit on 16 March 2020.

Duncan Peyton, 4D's Chief Executive Officer, and Alex Stevenson, 4D's Chief Scientific Officer, will be delivering a virtual presentation on 4D's clinical progress in oncology and provide an update on upcoming timelines and catalysts for 2020.

A recording of the presentation will be made available here at 13:15 GMT:

https://www.4dpharmaplc.com/en/investors/reports-presentations

For further information please contact:

4D

Duncan Peyton, Chief Executive Officer + 44 (0)113 895 0130

Investor Relations [e-mail]

N+1 Singer - Nominated Adviser and Joint Broker [phone]

Aubrey Powell / Justin McKeegan / Alex Bond (Corporate Finance)

Tom Salvesen (Corporate Broking)

Bryan Garnier & Co. Limited - Joint Broker [phone]

Dominic Wilson / Phil Walker

About 4D

Founded in February 2014, 4D is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drug, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx(R), that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism. 4D's Live Biotherapeutic products are orally delivered single strains of bacteria originally isolated from the gut microbiome of healthy human donors. The Company currently has five clinical studies in progress, namely a Phase II clinical study of Blautix in irritable bowel syndrome (IBS), a Phase I/II study of MRx0518 in combination with KEYTRUDA(R) (pembrolizumab) in solid tumours, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours, a Phase I study of MRx0518 in combination with preoperative radiotherapy for pancreatic cancer, and a Phase I/II study of MRx-4DP0004 in asthma. Preclinical-stage programmes include candidates for oncology, CNS diseases such as Parkinson's disease and other neurodegenerative conditions, and autoimmune diseases. The company has a research collaboration with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

For more information, refer to https://www.4dpharmaplc.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRAGPUQPWUPUGPW

(END) Dow Jones Newswires

March 16, 2020 03:00 ET (07:00 GMT)